Core Viewpoint - The company, Qianxin Biotechnology-B (02509.HK), announced that its subsidiary, Jiangsu Saifusi Biotechnology Co., Ltd., successfully passed the EU Qualified Person (QP) audit, achieving compliance with EU GMP standards [1] Group 1: Audit and Compliance - The audit was conducted by a senior QP over a three-day period, reviewing Saifusi's quality management system, advanced facilities, and professional technical team [1] - The audit team recognized the high standards of Saifusi's quality management system and confirmed that both hardware and software management meet EU GMP requirements [1] - Passing the QP audit provides a strong proof of compliance with international GMP standards, which is a prerequisite for products entering the EU market [1] Group 2: Strategic Implications - The successful QP certification marks an important milestone in the company's strategy for international expansion and product innovation [1] - This achievement lays a solid foundation for the company's future innovative products to enter global markets [1]
荃信生物-B(02509.HK)：荃信生物产业化基地成功通过欧盟QP审计